Company Details

Novogen Ltd (ASX: NRT; NASDAQ: NVGN)

ASX Listed
ASX Listed
Biomedical / Biotechnology, Biotech
General Investor Profiling

Company Information

  • Executive Summary

    Executive Summary

    Novogen Limited (ASX: NRT; NASDAQ: NVGN) is an emerging, oncology-focused drug development company, based in Sydney, Australia.

    Novogen has a portfolio of drug development candidates, each with the potential to yield first-in-class and best-in-class agents across a range of oncology indications. The lead program is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway, is being developed to treat glioblastoma multiforme, the primary and most aggressive form of brain cancer (GBM). Few current treatment options exist for patients with GBM.

    Licensed from Genentech in late 2016, GDC-0084 has successfully completed a phase I clinical trial in humans under an investigational new drug application (IND) with the US FDA, and showed a good safety profile and strong efficacy signals which will be further assessed in phase II. It is anticipated that GDC-0084 will enter phase II clinical trials in humans in 2017.

    Two further molecules have been developed in-house from the Company’s proprietary drug discovery platform (superbenzopyrans) to treat ovarian cancer and a range of solid tumours. TRXE-002-1 (Cantrixil), the most advanced of these, commenced a first-in-human, phase I clinical study under an IND with the US FDA in patients with ovarian cancer in late 2016. TRXE-009 (Trilexium) is in preclinical development.

    In February 2017, Novogen was awarded a grant to develop a next generation anti-tropomyosin program. Under the grant, Novogen will work in conjunction with partners to design a drug that is expected to target the structural components of cancer cells, and be applicable across a range of cancer types.

    Request Information 

    • Experienced drug developer with two drugs in human clinical trials
    • Lead program, GDC-0084 is for the most aggressive form of brain cancer, Glioblastoma Multiforme and has been in-licensed from Genentech (part of Roche)
    • In phase I human clinical trials, GDC-0084 had shown strong safety and efficacy signals
    • A second drug, Cantrixil is now in Phase I human clinical trials, targeting ovarian cancer. Patients are currently being dosed under the trial
    • Novogen has a lean and nimble team, with a strong background of pharmaceutical drug development

    16 employees

    Novogen is a listed company. Investors can trade in and out on market, via either the ASX listing (code is NRT) or the NASDAQ listing (code is NVGN)

  • Company Highlights

    Company Highlights

    • Enhanced Pipeline
      • Lead drug, GDC-0084 was in-licensed from Genentech (subsidiary of Roche) in October 2016
      • It is under development for Glioblastoma (primary brain cancer) – a ~$1b annual market
      • Completed phase I human trial in 47 patients Phase II human trial to start in 2017
      • Open IND with US FDA, strong IP protection, and pre-manufactured drug substance
      • Second drug, TRXE-002-1 (Cantrixil) developed from pre-existing Novogen research
      • Under development for ovarian cancer Phase I human trial currently underway in Australia and US
    • Strengthened Team
      • New senior management with extensive international industry experience
      • Global Scientific Advisory Board of eminent cancer research specialists
    • Focused Strategy
      • Accessing the best global innovation available Bring in programs with some of the risky, time-consuming work already done
      • Partner with big pharma for expensive and labour-intensive late-stage development and commercialisation
    • Transformed the company from a pre-clinical focus at start of 2016 to now being a company with two clinically staged programs
    • Submitted an investigational new drug application for Cantrixil in August 2016 – In-licensed GDC-0084 in October 2016
    • Commenced Phase 1 trial for Cantrixil in December 2016
    • Communicated trial design for GDC-0084 in April 2017
    • Phase 2 ready GDC-0084 drug for the treatment of glioblastoma multiforme
    • Phase 1 clinical trial in progress for Cantrixil for the treatment of ovarian cancer
    • Pre-clinical work being conducted on Trilexium and a platform based on anti-tropomyosin
  • Board & Management

    Board & Management

    Dr James Garner

    Dr James Garner

    Chief Executive Officer & Executive Director
    Dr Garner is an experienced life sciences executive who has previously worked with companies ranging from small biotechs to multinational pharmaceutical companies such as Biogen and Takeda. His career has focused on regional and global...

    Dr Garner is an experienced life sciences executive who has previously worked with companies ranging from small biotechs to multinational pharmaceutical companies such as Biogen and Takeda. His career has focused on regional and global development of new medicines from preclinical to commercialisation.

    Dr Garner is a physician by training and holds an MBA from the University of Queensland. He began his career in hospital medicine and worked for a number of years as a corporate strategy consultant with Bain & Company before entering the pharmaceutical industry. Prior to joining Novogen in 2016, he led R&D strategy for Sanofi in Asia-Pacific and was based in Singapore

    John P O’Connor

    John P O’Connor

    Chairman & Non-Executive Director
    Mr John O’Connor has over 30 year’s experience in the financial industry and was appointed to the novogen board in may 2012. He has held numerous management roles as a fund manager and stockbroker in...

    Mr John O’Connor has over 30 year’s experience in the financial industry and was appointed to the novogen board in may 2012. He has held numerous management roles as a fund manager and stockbroker in the UK, US and Australia and also a partnership in a securities business. He has been a consultant to several biotech companies, including Novogen Limited and Marshall Edwards Inc., assisting with fundraising.

    Mr O’Connor served on the Board of Lonsec Securities, a Zurich Insurance owned business, for several years.

    Bryce Carmine

    Bryce Carmine

    Deputy Chairman & Non-Executive Director
    Bryce Carmine spent 36 years working for Eli Lilly & Co. and retired as Executive Vice President for Eli Lilly & Co, and President, Lilly Bio-Medicines. Prior to this he lead the Global Pharmaceutical Sales...

    Bryce Carmine spent 36 years working for Eli Lilly & Co. and retired as Executive Vice President for Eli Lilly & Co, and President, Lilly Bio-Medicines. Prior to this he lead the Global Pharmaceutical Sales and Marketing and was a member of the company’s executive committee.

    Mr Carmine previously held a series of product development portfolio leadership roles culminating when he was named President, Global Pharmaceutical Product Development, with responsibility for the entire late-phase pipeline development across all therapeutic areas for Eli Lilly.

    During his career with Lilly Bryce held several country leadership positions including President Eli Lilly Japan, Managing Dir. Australia/NZ & General Manager of a JV for Lilly in Seoul, Korea.

    Steven Coffey

    Steven Coffey

    Non-Executive Director
    Mr Steven Coffey is a Chartered Accountant, having spent his career in public practice since graduating from NSW University in 1983. He has been a partner in the chartered accounting firm Watkins Coffey Martin since...

    Mr Steven Coffey is a Chartered Accountant, having spent his career in public practice since graduating from NSW University in 1983. He has been a partner in the chartered accounting firm Watkins Coffey Martin since 1993.

    Mr Coffey is a registered company auditor and audits a number of large private companies as well as not for profit entities. He has previously served on the board of an Australian listed public company and is currently a board member of private family foundation.

    Ian M Phillips

    Ian M Phillips

    Non-Executive Director
    Ian M Phillips, MNZM has been involved with International Banking, global financial markets and Corporate Finance for over 30 years having worked in New York (20 years plus), London (5), Singapore (6 months), Sydney (5)...

    Ian M Phillips, MNZM has been involved with International Banking, global financial markets and Corporate Finance for over 30 years having worked in New York (20 years plus), London (5), Singapore (6 months), Sydney (5) and Wellington(4)

    Mr Phillips is President of KUMARA, Chairman of NNP, Deputy Chairman of the American Australian Association immediate past President of the American Friends of the NGA, Chairman of ANZA, an Advisory Board of the US-NZ Council and a Board member of the American friends of Christchurch.

    Mr Phillips studied at Otago University, University of Colorado and London School of economics. Mr Phillips holds dual citizenship USA & NZ. In 2013 was awarded the NZ Order of Merit

    Iain Ross

    Iain Ross

    Non-Executive Director
    Mr Iain Ross is an experienced multinational pharmaceutical and biotechnology executive and is currently Chairman of e-Therapeutics plc (LSE: ETX) and Biomer Technology limited. He is also a non executive director Premier Veterinary Group plc...

    Mr Iain Ross is an experienced multinational pharmaceutical and biotechnology executive and is currently Chairman of e-Therapeutics plc (LSE: ETX) and Biomer Technology limited. He is also a non executive director Premier Veterinary Group plc (LSE:PVG) and of ASX-listed Anatara Lifesciences Ltd.

    During his career, Mr Ross has held senior positions at multinational companies, Sandoz AG, Hoffman La Roche, and Celltech Group PLC and been a Chairman, CEO and Director of several biotech companies. He is a qualified Chartered Director and Vice Chairman of the Council of Royal Holloway, London University

  • Company News
  • Contact Details

    Contact Details